Abstract

BackgroundMany studies of the eukaryotic transcription mechanism and its regulation rely on in vitro assays. Conventional RNA polymerase II transcription assays are based on radioactive labelling of the newly synthesized RNA. Due to the inefficient in vitro transcription, the detection of the RNA involving purification and gel electrophoresis is laborious and not always quantitative.ResultsHerein, we describe a new, non-radioactive, robust and reproducible eukaryotic in vitro transcription assay that has been established in our laboratory. Upon transcription, the newly synthesized RNA is directly detected and quantified using the QuantiGene assay. Alternatively, the RNA can be purified and a primer extension followed by PCR detection or qPCR quantification can be performed. When applied to assess the activity of RNA polymerase II inhibitors, this new method allowed an accurate estimation of their relative potency.ConclusionsOur novel assay provides a non-radioactive alternative to a standard in vitro transcription assay that allows for sensitive detection and precise quantification of the newly transcribed, unlabelled RNA and is particularly useful for quantification of strong transcriptional inhibitors like α-amanitin. Moreover, the method can be easily adapted to quantify the reaction yield and the transcription efficiency of other eukaryotic in vitro systems, thus providing a complementary tool for the field of transcriptional research.

Highlights

  • Many studies of the eukaryotic transcription mechanism and its regulation rely on in vitro assays

  • Α-amanitin or other compounds were added in various concentrations to the reaction mix

  • Except for the termination, an in vitro runoff transcription system must emulate a proper environment for all these processes [15]

Read more

Summary

Introduction

Many studies of the eukaryotic transcription mechanism and its regulation rely on in vitro assays. Conventional RNA polymerase II transcription assays are based on radioactive labelling of the newly synthesized RNA. The control of transcription plays a key role, and research is still ongoing to decipher its mechanisms. Many of these studies rely on in vitro RNA polymerase II transcription assays [1,2,3]. Since inhibition of transcription leads to apoptosis regardless of the p53 status of the cells, interfering with transcription is a promising therapeutic strategy for developing new anticancer agents [5,6]. Several common chemotherapeutic agents indirectly inhibit translation by damaging the DNA (cisplatin), by topomerase

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call